Small company DexCom, finds itself a leader in continuous glucose monitoring, the hottest new segment of glucose monitoring, a business otherwise dominated by giant companies. Continuous glucose monitoring (CGM) is all the buzz at diabetes and critical care clinical meetings these days. CGM systems give diabetic patients in the home (or the hospital) glucose readings at any hour of the day without the need to get out the finger-stick testing paraphernalia. More than that, though, CGM is a new tool for achieving tight glycemic control, and avoiding the excursions above and below the normal glucose levels, which are responsible for the hospitalizations as well as the long-term harmful consequences of diabetes. As a frontrunner in the field, DexCom shares with Medtronic the challenge of proving the value of CGM to payers, especially since the task involves throwing over the gold standard by which successful glycemic control is measured-the HbA1c test.

In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.

In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.